Presentation

Company Profile
BONESUPPORT is a fast-growing orthobiologics company in the commercial phase that targets the major orthopedic markets in the US and Europe. It develops and commercializes injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed synthetic bone graft substitutes are CERAMENT BONE VOID FILLER, CERAMENT G and CERAMENT V, all based on the novel and proprietary CERAMENT technology platform.

Recent highlights
Net sales in Q2 amounted to SEK 51.8m (36.2), an increase of 43% year-on-year. In April, the company announced that it had been awarded a Synthetic Implantable Products agreement with Premier. Premier, with approximately 4,100 hospitals in its network, is one of the leading purchasing networks in the US. In June, the company received “breakthrough device designation” from the US Food and Drug Administration (FDA) for CERAMENT G for trauma indications. At the end of June, the last patient follow-up in the FORTIFY study was conducted. The FORTIFY study aims to demonstrate safety and effectiveness of CERAMENT G used with standard-of-care treatment compared to standard-of-care alone in the care of subjects with open fractures of the tibial diaphysis.

Outlook
The company’s focus currently lies in bringing their product CERAMENT G to the US market. For the De Novo pathway, submission of additional data is expected in October, while for the trauma indication, the application in expected to be submitted by end of 2021. The company’s annual sales growth target is 40%.